Objective Low levels of total cholesterol (TC) are associated with adverse outcomes in older populations. Whether this phenomenon is independent of statin use is unknown. We investigated the association between low TC levels and long-term major adverse cardiovascular events (MACE) in a prospective study of men aged ≥70 years without ischaemic heart disease (IHD) and whether this was influenced by statin use.
Methods The CHAMP (Concord Health and Ageing in Men Project) cohort is a prospective cohort study of community-dwelling men aged ≥70 years. The relationship between TC and long-term MACE was analysed using Cox-regression modelling adjusted for comorbidities and stratified by statin use.
Results The study cohort comprised 1289 men (mean (±SD) age, 77.0±5.5 years; mean follow-up, 6.4±2.7 years). Decreasing TC level was associated with increased comorbidity burden, frailty and MACE (linear trend p<0.001). In men not on statin therapy (n=731), each 1 mmol/L decrease in TC was associated with increased MACE (HR 1.27, 95% CI 1.10 to 1.45, p=0.001) and mortality (HR 1.22, 95% CI 1.03 to 1.44, p=0.02) adjusted for comorbidities. In contrast, low TC in men on statins (n=558) was not associated with MACE (HR 0.91, 95% CI 0.74 to 1.11) or mortality (HR 0.86, 95% CI 0.68 to 1.09).
Conclusion Low TC is associated with increased risk of MACE in older men without IHD who are not taking statin therapy but not in those on statins.
- lipoproteins and hyperlipidemia
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
LK and FB are joint senior authors.
Contributors All authors have read and approved this manuscript. All authors contributed to the paper. SRG, ACCN and LK were involved in the planning, data analysis and writing of the manuscript. RC, DBB, DLC, LW, DH, VN and FB were involved in the planning and writing of the manuscript.
Funding The CHAMP study was supported by the National Health and Medical Research Council (project grant no. 301916), Australia and the Ageing and Alzheimer’s Institute, Australia.
Competing interests None declared.
Patient consent for publication Obtained.
Ethics approval The study was approved by the institutional Research Ethics Committee (Sydney Local Health District).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article or uploaded as online supplementary information.